Advertisement
Advertisement
Aytu BioPharma, Inc. (AYTU)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 0.6900 |
| Open | 0.6552 |
| Bid | 0.6555 x 1000 |
| Ask | 0.6650 x 1800 |
| Day's Range | 0.6382 - 0.8097 |
| 52 Week Range | 0.4500 - 4.9500 |
| Volume | |
| Avg. Volume | 1,220,901 |
| Market Cap | 18.859M |
| Beta (5Y Monthly) | -0.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Benzinga
Aytu BioPharma Plans To Divest / Discontinue Non Core Assets
View more earnings on AYTUSee more from BenzingaFDA May Authorize Pfizer-BioNTech's COVID-19 Booster For 5-11 Year Kids Soon: NYTWarren Buffett Exits Wells Fargo And Buys Stake In Its Rival BankDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- Zacks
Has Aytu BioPharma Inc. (AYTU) Outpaced Other Medical Stocks This Year?
Here is how Aytu BioPharma Inc. (AYTU) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.
- Zacks
Aytu BioPharma's (AYTU) AR101 Gets FDA's Orphan Drug Status
The FDA bestows an Orphan Drug designation to Aytu BioPharma's (AYTU) AR101 for the treatment of vascular Ehlers-Danlos Syndrome.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
